Literature DB >> 9328260

Long term melphalan-prednisolone chemotherapy for POEMS syndrome.

S Kuwabara1, T Hattori, Y Shimoe, I Kamitsukasa.   

Abstract

The effects of long term melphalan-prednisolone (MP) therapy was studied on 12 patients with POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes) syndrome. Six were treated with MP every six weeks for 16 to 52 months; three also with cyclophosphamide, and three with localised irradiation for osteoclastic lesions. Five of the six survived during the follow up period and showed various degrees of lessening of their neuropathy and other symptoms. There were no serious side effects. The other six patients received treatments that included corticosteroids, short term chemotherapy, or irradiation, but not long term chemotherapy. Five showed transient lessening of their non-neurological symptoms, and one, obvious neurological improvement. Five of these six patients died from nine to 70 months after POEMS onset. The findings suggest that long term MP therapy may be an effective treatment for the POEMS syndrome.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9328260      PMCID: PMC2169695          DOI: 10.1136/jnnp.63.3.385

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  8 in total

Review 1.  Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome.

Authors:  Satoshi Kuwabara; Angela Dispenzieri; Kimiyoshi Arimura; Sonoko Misawa; Chiaki Nakaseko
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

2.  Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome.

Authors:  Jian Li; Wei Zhang; Li Jiao; Ming-Hui Duan; Hong-Zhi Guan; Wei-Guo Zhu; Zhuang Tian; Dao-Bin Zhou
Journal:  Blood       Date:  2011-03-10       Impact factor: 22.113

Review 3.  POEMS Syndrome: an Enigma.

Authors:  Rahma Warsame; Uday Yanamandra; Prashant Kapoor
Journal:  Curr Hematol Malig Rep       Date:  2017-04       Impact factor: 4.213

4.  Cutaneous Manifestations in POEMS Syndrome: Case Report and Review.

Authors:  Flauberto Sousa Marinho; Rodrigo Pirmez; Renata Nogueira; Tullia Cuzzi; Celso Tavares Sodré; Marcia Ramos-e-Silva; Marcia Silva
Journal:  Case Rep Dermatol       Date:  2015-04-21

5.  Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial.

Authors:  Kanako Katayama; Sonoko Misawa; Yasunori Sato; Gen Sobue; Ichiro Yabe; Osamu Watanabe; Masatoyo Nishizawa; Susumu Kusunoki; Seiji Kikuchi; Ichiro Nakashima; Shu-Ichi Ikeda; Nobuo Kohara; Takashi Kanda; Jun-Ichi Kira; Hideki Hanaoka; Satoshi Kuwabara
Journal:  BMJ Open       Date:  2015-01-08       Impact factor: 2.692

6.  Alcohol Misuse Link to POEMS Syndrome in a Patient.

Authors:  John Neary; Susan E Goodwin; Lawrence B Cohen; Manuela G Neuman
Journal:  Cancers (Basel)       Date:  2017-09-23       Impact factor: 6.639

Review 7.  Treatment of POEMS syndrome.

Authors:  Angela Dispenzieri; Morie A Gertz
Journal:  Curr Treat Options Oncol       Date:  2004-06

8.  Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study.

Authors:  S Misawa; Y Sato; K Katayama; H Hanaoka; S Sawai; M Beppu; F Nomura; K Shibuya; Y Sekiguchi; Y Iwai; K Watanabe; H Amino; C Ohwada; M Takeuchi; E Sakaida; C Nakaseko; S Kuwabara
Journal:  BMJ Open       Date:  2015-11-11       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.